Panwar R, Sequeira R, Clarke T
Genes Immun. 2021; 22(5-6):255-267.
PMID: 33947987
PMC: 8497270.
DOI: 10.1038/s41435-021-00129-5.
Abutaleb N, Seleem M
Sci Rep. 2021; 11(1):7093.
PMID: 33782498
PMC: 8007812.
DOI: 10.1038/s41598-021-86595-3.
Mehta P, Nahass R, Brunetti L
Clin Infect Dis. 2020; 73(1):e62-e68.
PMID: 32386313
PMC: 8246810.
DOI: 10.1093/cid/ciaa545.
Bouillaut L, Dubois T, Francis M, Daou N, Monot M, Sorg J
Mol Microbiol. 2019; 111(6):1671-1688.
PMID: 30882947
PMC: 6561804.
DOI: 10.1111/mmi.14245.
Chandrasekar T, Naqvi N, Waddington A, Cooke R, Anijeet H, Gradden C
NDT Plus. 2019; 1(1):20-22.
PMID: 30792777
PMC: 6375245.
DOI: 10.1093/ndtplus/sfm008.
Novel risk factors for recurrent Clostridium difficile infection in children.
Nicholson M, Thomsen I, Slaughter J, Creech C, Edwards K
J Pediatr Gastroenterol Nutr. 2014; 60(1):18-22.
PMID: 25199038
PMC: 4276518.
DOI: 10.1097/MPG.0000000000000553.
Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D, Cornely O, Van Engen A, Odufowora-Sita O, Retsa P, O Odeyemi I
J Antimicrob Chemother. 2014; 69(11):2901-12.
PMID: 25096079
PMC: 4195473.
DOI: 10.1093/jac/dku257.
5-Aminosalicylic Acid Inhibits Acute Clostridium difficile Toxin A-Induced Colitis in Rats.
Vigna S
Int J Inflam. 2014; 2014:389621.
PMID: 25045574
PMC: 4090440.
DOI: 10.1155/2014/389621.
Clinical predictors of recurrent Clostridium difficile infection in out-patients.
Shivashankar R, Khanna S, Kammer P, Harmsen W, Zinsmeister A, Baddour L
Aliment Pharmacol Ther. 2014; 40(5):518-22.
PMID: 25039269
PMC: 4135383.
DOI: 10.1111/apt.12864.
Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells.
Boonma P, Spinler J, Venable S, Versalovic J, Tumwasorn S
BMC Microbiol. 2014; 14:177.
PMID: 24989059
PMC: 4094603.
DOI: 10.1186/1471-2180-14-177.
Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.
Rafiullah F, Kanwal S, Majeed U, Korsten M, Cheema F, Luthra M
BMJ Case Rep. 2012; 2011.
PMID: 22674696
PMC: 3229312.
DOI: 10.1136/bcr.04.2011.4123.
Probiotics in clostridium difficile Infection.
Na X, Kelly C
J Clin Gastroenterol. 2011; 45 Suppl:S154-8.
PMID: 21992956
PMC: 5322762.
DOI: 10.1097/MCG.0b013e31822ec787.
The vermiform appendix and recurrent Clostridium difficile infection: a curious connection.
Na X, Kelly C
Clin Gastroenterol Hepatol. 2011; 9(12):1017-9.
PMID: 21893132
PMC: 5320954.
DOI: 10.1016/j.cgh.2011.08.025.
Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea.
Kim J, Lee K, Jeong J, Kim B, Shin S, Kim J
World J Gastroenterol. 2010; 16(28):3573-7.
PMID: 20653067
PMC: 2909558.
DOI: 10.3748/wjg.v16.i28.3573.
Clostridium difficile associated infection, diarrhea and colitis.
Hookman P, Barkin J
World J Gastroenterol. 2009; 15(13):1554-80.
PMID: 19340897
PMC: 2669939.
DOI: 10.3748/wjg.15.1554.
Metronidazole resistance in Clostridium difficile is heterogeneous.
Pelaez T, Cercenado E, Alcala L, Marin M, Martin-Lopez A, Martinez-Alarcon J
J Clin Microbiol. 2008; 46(9):3028-32.
PMID: 18650353
PMC: 2546748.
DOI: 10.1128/JCM.00524-08.
Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.
Anton P, OBrien M, Kokkotou E, Eisenstein B, Michaelis A, Rothstein D
Antimicrob Agents Chemother. 2004; 48(10):3975-9.
PMID: 15388461
PMC: 521872.
DOI: 10.1128/AAC.48.10.3975-3979.2004.
Clostridium difficile colitis in children with cystic fibrosis.
Hussain S, Chu C, Greenberg D, Orenstein D, Khan S
Dig Dis Sci. 2004; 49(1):116-21.
PMID: 14992445
DOI: 10.1023/b:ddas.0000011612.74033.78.
Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy.
Moyenuddin M, Williamson J, Ohl C
Curr Gastroenterol Rep. 2002; 4(4):279-86.
PMID: 12149168
DOI: 10.1007/s11894-002-0077-0.
